

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (gh-35) BELANTAMAB MAFODOTIN

PRONUNCIATION bel an' ta mab ma'' foe doe' tin

THERAPEUTIC CLAIM Treatment of multiple myeloma

## CHEMICAL NAMES

1. Immunoglobulin G1, anti-(Tumor necrosis factor receptor superfamily protein TNFRSF17) (humanized monoclonal GSK2857914  $\gamma$ 1-chain), disulfide with humanized monoclonal GSK2857914  $\kappa$ -chain, dimer
2. Immunoglobulin G1-kappa, anti-(*Homo sapiens* Tumor necrosis factor receptor superfamily member 17 (B-cell maturation protein, antigen CD269)); humanized monoclonal antibody conjugated to auristatin F;  $\gamma$ 1 heavy chain (1-451) [humanized VH (*Homo sapiens* IGHV1-69\*06 (84%) –(IGHD)-IGHJ4\*01 (86%)) [8.8.14] (1-121) -*Homo sapiens* IGHG1\*01 (122-451)] (224-214')-disulfide with  $\kappa$  light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33\*01 (91%) –IGKJ2\*02 [6.3.9] (1'-107') -*Homo sapiens* IGKC\*01 (108'-214')), dimer (230-230":233-233")-bisdisulfide; conjugated, on an average of 4 cysteinyl residues (C), to monomethyl auristatin F via maleimidocaproyl linker.

## STRUCTURAL FORMULA

### Heavy chain

QVQLVQSGAE	VKKPGSSVKV	SCKASGGTFS	NYWMHWVRQA	PGQGLEWMGA	50
TYRGHSDTY	NQKFKGRVTI	TADKSTSTAY	MELSSLRSED	TAVYYCARGA	100
IYDGYDVLN	WGQGLVTVS	SASTKGPSVF	PLAPSSKSTS	GGTAALGCLV	150
KDYFPEPVT	SWNSGALTSG	VHTFPAVLQS	SGLYSLSSV	TVPSSSLGTQ	200
TYICNVNHK	SNTKVDKVE	PKSCDKTHTC	PPCPAPELGG	GPSVFLFPPK	250
PKDTLMSRT	PEVTCVVDV	SHEDPEVKFN	WYVDGVEVHN	AKTKPREEQY	300
NSTYRVVSV	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKAKGQPREP	350
QVYTLPPSR	ELTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	PENNYKTTTP	400
VLDSGDSFFL	YSKLTVDKSR	WQQGNVFS	VMHEALHNHY	TQKSLSLSPG	450
K					451

### Light chain


DIQMTQSPSS	LSASVGRVTV	ITCSASQDIS	NYLNWYQQKP	GKAPKLLIYY	50'
TSNLSHGVPS	RFSGSGSGTD	FTLTISSLQP	EDFATYYCQQ	YRKLPTWTFGQ	100'
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNFFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

### Disulfide bridges location\*

22-96	22"-96"	23'-88'	23"-88"	134'-194'	134"-194"	148-204	148"-204"
214'-224	214"-224"	230-230"	233-233"	265-325	265"-325"	371-429	371"-429"

\* Partly reduced to be linked to mafadotin (C)

Modified residues (C)



Glycosylation sites (N)

Asn-301 Asn-301"

100% afucosylated complex bi-antennary CHO type glycans

MOLECULAR FORMULA	$C_{6484}H_{10008}N_{1728}O_{2030}S_{44} \cdot (C_{49}H_{66}N_6O_{11})_4$
MOLECULAR WEIGHT	149.5 kDa (non-glycosylated)
TRADEMARK	None as yet
SPONSOR	GlaxoSmithKline
CODE DESIGNATIONS	GSK2857916
<u>CAS</u> REGISTRY NUMBER	2050232-20-5
UNII	DB1041CXDG
WHO NUMBER	10754

gbk